SS-31 Peptide Benefits: The Trial It Failed and the Approval It Won

In 2020 this compound failed the largest trial ever run on it. Both primary endpoints missed, neither close. Five years later the FDA approved it.

Those two facts are usually reported by different people with different agendas, and holding them together is the only way the compound makes sense. The failure and the approval happened in different diseases, and the reason one worked while the other did not is the most instructive thing in this entire research category. It explains what SS-31 does, what it cannot do, and why almost every product page describing it as a general mitochondrial enhancer has the story backwards.

What SS-31 is, and the cardiolipin mechanism

SS-31, known in clinical development as elamipretide, is four amino acids long. It came out of work by Hazel Szeto and Peter Schiller, whose initials give the compound family its name, and was developed by Stealth BioTherapeutics.

Its target is a single molecule: cardiolipin.

Cardiolipin is a phospholipid found almost nowhere except the inner mitochondrial membrane. It is structurally odd, carrying four fatty acid tails where most phospholipids carry two, and that shape lets it force the membrane into the tight folds called cristae. Those folds are where energy production physically happens. Cardiolipin also organizes the electron transport chain proteins into functional clusters, holding the machinery in the arrangement that works.

When cardiolipin is damaged or abnormal, cristae flatten, the transport chain loses its organization, electrons leak, and reactive oxygen species increase. SS-31 binds cardiolipin and stabilizes it, which restores the membrane architecture rather than adding anything to the process.

That is an unusually specific mechanism for this category. Most compounds sold for mitochondrial support describe vague improvements in function. This one names a molecule.

The SS-31 trial that failed, and what it showed

MMPOWER-3 was the pivotal phase 3, and it deserves describing properly because the numbers are public and unambiguous.

The trial enrolled people with genetically confirmed primary mitochondrial myopathy, randomizing them to 40mg daily of elamipretide or placebo for 24 weeks. The two primary endpoints were distance covered on a six-minute walk test and total fatigue on a symptom assessment built for the condition.

Neither moved. The difference on the walk test was minus 3.2 meters, favoring placebo, with a p-value of 0.69. The fatigue score difference was minus 0.07, p-value 0.37. The results were published in Neurology, and there is no reading of them that finds a signal.

A post hoc analysis later reported that participants whose disease came from nuclear DNA variants, rather than mitochondrial DNA variants, did show improvement on the walk test. Post hoc subgroup findings are hypothesis-generating rather than conclusive, and everyone involved said so. But it was the first hint that the compound might work in some mitochondrial diseases and not others, which turned out to matter.

SS-31 peptide benefits: what the FDA actually approved

In September 2025 the FDA granted accelerated approval to elamipretide, under the brand name Forzinity, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms. It was reported as the first FDA-approved treatment for Barth syndrome and the first approved therapeutic targeting mitochondria directly.

Barth syndrome is an ultra-rare X-linked genetic disorder caused by mutations in the TAFAZZIN gene. It produces exercise intolerance, muscle weakness, severe fatigue, heart failure and impaired growth.

The approval rested on TAZPOWER, a trial of twelve patients. Worth stating plainly: its primary endpoints also did not reach statistical significance. What supported the approval was improvement in knee extensor muscle strength observed during the open-label extension period. Accelerated approval means continued approval may depend on confirmatory trials verifying clinical benefit.

So the honest summary is that SS-31 has an FDA approval, in one ultra-rare disease, on a twelve-patient dataset, under a pathway that requires further evidence. That is dramatically more regulatory standing than anything else in this category has, and it is a long way from what “clinically proven” would imply.

Why one SS-31 trial failed and the other did not

Here is where the whole thing resolves, and it is genuinely elegant.

The TAFAZZIN gene encodes an enzyme that remodels cardiolipin into its mature form. Barth syndrome is, at the molecular level, a cardiolipin disorder. The fatty acid tails are wrong, the cristae are malformed, and mitochondrial function degrades as a direct consequence.

SS-31 binds cardiolipin. It was tested in a disease whose defining defect is cardiolipin, and it produced enough of a signal to support an approval.

Primary mitochondrial myopathy is a broad category covering many different genetic causes, most of which have nothing to do with cardiolipin. A compound that stabilizes cardiolipin has no particular reason to help when the failure is somewhere else in the system, and in a population averaging across many causes, it did not.

The lesson generalizes past this compound. SS-31 is not a mitochondrial enhancer. It is a cardiolipin stabilizer, and it appears to work when cardiolipin is the problem. Any claim that it broadly improves mitochondrial function in healthy people is asserting something the largest trial on the compound actively failed to demonstrate.

The other SS-31 trials worth knowing about

Barth syndrome and mitochondrial myopathy were not the only places this compound was tested, and the wider program is part of why the evidence picture is more complicated than either headline suggests.

Elamipretide has been studied in Leber hereditary optic neuropathy, a mitochondrial condition affecting the optic nerve, and in dry age-related macular degeneration, where mitochondrial dysfunction in the retinal pigment epithelium is a proposed contributor. The retina is a reasonable target on paper, since photoreceptors are among the most metabolically demanding cells in the body and sit directly on a layer whose mitochondrial health declines with age.

None of that work has produced an approval. What it does show is a development program that took the compound seriously across multiple conditions over more than a decade, which is a meaningfully different history from a compound that appeared in a supplier catalog with a mechanism and no trials behind it.

It also shows how narrow the eventual success was. A broad program across several mitochondrial conditions produced one accelerated approval, in the single disease where the defect is cardiolipin itself.

SS-31 vs MOTS-c: two routes into the same organelle

These two get sold as a pair and they have almost nothing in common beyond the organelle.

Structure against signal, and a very large gap in evidence. The MOTS-c research covers the other side of that comparison, including why the exercise findings are more complicated than they first appear.

What SS-31 research does not establish

Nothing in this file supports use in healthy people. Every trial enrolled participants with diagnosed mitochondrial disease, and the approved indication covers a genetic disorder affecting a very small number of people worldwide.

The anti-aging framing is inference rather than evidence. Cardiolipin does change with age, and mitochondrial dysfunction is a named hallmark of aging, so the reasoning is not baseless. It is also exactly the kind of mechanistic extrapolation that MMPOWER-3 should make anyone cautious about, because that trial tested the compound in people whose mitochondria were genuinely impaired and still found nothing on its primary endpoints.

Long-term safety outside the trial populations is uncharacterized. And research-grade material is not Forzinity. The approved product is a specific formulation at a specific dose under medical supervision for a diagnosed condition, and a vial of research compound sharing the molecule is not that, however the product page is worded.

There is a broader point buried in the accelerated approval pathway that is worth extracting. Accelerated approval exists so that patients with serious conditions and no alternatives can access a drug before the full evidence is assembled, with the understanding that confirmatory trials will follow and that approval can be withdrawn if they fail. It is a deliberate trade of certainty for speed, made because twelve patients with an ultra-rare fatal disease cannot wait for a two-thousand-person trial that will never be feasible to run. Reading that approval as a verdict on the compound’s general usefulness inverts what the pathway is for.

SS-31 research in women

This is the most awkward gap in the file, and it is worth naming rather than skipping.

Barth syndrome is X-linked and affects essentially only males. The approved indication, and therefore the strongest evidence SS-31 has, comes from a population that is almost entirely male. MMPOWER-3 enrolled both sexes but was not designed to compare them and did not find an effect in either.

That leaves a compound sold heavily into women’s longevity marketing whose entire regulatory foundation rests on research in men and boys with a rare genetic condition. The distance between those two things is not a technicality.

There is a real biological reason to expect sex differences too. Estrogen influences mitochondrial biogenesis and antioxidant capacity directly, and cardiolipin composition itself varies with hormonal state in animal models. Whether a cardiolipin-targeting compound behaves differently across that variation is an obvious question, and nobody has asked it.

Where to source SS-31 and what to verify

A four-amino-acid peptide with two modified residues is a more demanding synthesis than its length suggests, since the dimethyltyrosine and the D-arginine are not standard building blocks. Identity confirmation matters more here than for a simple sequence.

The certificate of analysis should name an independent laboratory with no ownership relationship to the vendor, carry a batch number matching the vial received, report purity by HPLC, and confirm identity by mass spectrometry. Purity establishes consistency; only identity establishes what the material is.

Healio publishes every batch certificate openly at the research page, before purchase rather than on request afterward. SS-31 sits in the anti-aging collection and the peptides for energy collection, since the mitochondrial research spans both. It ships lyophilized, and the reconstitution guide covers solvent choice and stability.

SS-31 peptide benefits: frequently asked questions

What does SS-31 do?

SS-31 binds cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane, and stabilizes it. That supports the membrane folds where energy production occurs and helps hold the electron transport chain in its functional arrangement. It restores existing structure rather than adding anything to the process.

Is SS-31 FDA approved?

Elamipretide, the clinical name for SS-31, received FDA accelerated approval in September 2025 as Forzinity, to improve muscle strength in Barth syndrome patients weighing at least 30 kilograms. That approval covers one ultra-rare genetic disease. Research-grade material sold under the name SS-31 is not the approved product.

Did SS-31 fail its clinical trial?

MMPOWER-3, a phase 3 trial in primary mitochondrial myopathy, missed both primary endpoints. The six-minute walk test difference was minus 3.2 meters with a p-value of 0.69. A later post hoc analysis found improvement in participants with nuclear DNA variants, which is hypothesis-generating rather than conclusive.

What is the difference between SS-31 and MOTS-c?

SS-31 is a synthetic four-amino-acid compound that stabilizes cardiolipin structurally. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that signals through AMPK to change gene expression. SS-31 has phase 3 data and an approval; MOTS-c has no human trials.

Does SS-31 work for anti-aging?

No trial has tested it for that. The reasoning connecting cardiolipin decline to aging is mechanistically coherent, but the largest trial of the compound was conducted in people with diagnosed mitochondrial disease and did not meet its primary endpoints. Extending that to healthy aging is inference well ahead of the evidence.

Related reading

• MOTS-c Benefits: the mitochondrial-DNA peptide, and the exercise question
• Best Peptides for Anti-Aging: the four compounds that survive scrutiny
• Best Peptides for Energy: why none of this category is a stimulant

Research use only. Every compound referenced on this page is supplied strictly for laboratory research. Nothing here is dosing guidance, and you will not find administration instructions anywhere on this site. These materials are not for human consumption, have not been evaluated by the FDA, and nothing here is medical advice. Consult a qualified healthcare professional for questions about your own health.